Physiological Insulinemia Acutely Modulates Plasma Leptin
In a study involving 2,000 obese adults, participants who took GLP-1 Treatments, Semaglutide or Tirzepatide while adhering to a diet and exercise regimen experienced significantly greater weight loss than those who relied solely on lifestyle adjustments
While CBD is something plenty of Bodybuilders uses, unfortunately, Amino Asylum does not stock CBD products
Side-by-Side Comparison Parameter Receptors Cagrilintide AMY1R/2R/3R + CTR Semaglutide GLP-1R Tirzepatide GLP-1R + GIPR Retatrutide GLP-1R + GIPR + Glucagon-R Parameter Half-life Cagrilintide ~7-8 days Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Parameter Dosing frequency Cagrilintide Once weekly Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Parameter Max studied dose Cagrilintide 4.5 mg/week (mono) Semaglutide 2.4 mg/week Tirzepatide 15 mg/week Retatrutide 12 mg/week Parameter Peak monotherapy weight loss Cagrilintide 11.8% at 68 wk Semaglutide 14.9-17% at 68 wk Tirzepatide 22.5% at 72 wk Retatrutide ~24% at 48 wk Parameter FDA status (June 2026) Cagrilintide Investigational Semaglutide Approved (2021) Tirzepatide Approved (2023) Retatrutide Investigational Parameter HbA1c reduction (T2D) Cagrilintide ~0.9 pp mono

Description Retatrutide peptide is a triple agonist targeting GLP-1, GIP and glucagon receptors, developed for the management of obesity and significant weight reduction
Formulated with benzyl alcohol to help inhibit bacterial growth, it allows for multiple withdrawals from a single vial while maintaining stability when handled properly